DNA CHARCOAL PLASMA SORPTION FOR TREATMENT OF SLE

DNA 炭血浆吸附治疗系统性红斑狼疮

• 批准号: 2717405
• 负责人: STEPHEN R ASH
• 金额: $ 10万
• 依托单位: HEMOCLEANSE, INC
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-08-15 至 1999-07-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2717405
• 关键词: antinuclear autoantibody; biomedical equipment development; blood flow measurement; charcoal; clinical biomedical equipment; enzyme linked immunosorbent assay; hemodialysis; immunopathology therapy; method development; monoclonal antibody; silanes; systemic lupus erythematosus

DESCRIPTION: (Adapted from the applicant's abstract) The long-term objective of this proposal is to develop an extracorporeal sorbent based treatment for systemic lupus erythematosus (SLE) and other immunologic disorders. A defining feature of SLE is the presence in the blood of anti-DNA antibodies (Ab), the level of which is correlated with the severity of disease symptoms. Current treatments are marginally effective or limited by severe side effects. The BioLogic-DT sorbent-based hemodialysis system has proven useful in the treatment of liver failure with coma. This technology has been enhanced by combining it with a PF auxiliary system which permits the direct treatment of plasma with powdered sorbents to remove large or protein bound molecules. Use of DNA immunosorbent in the PF unit of the BioLogic-DTPF will provide a therapy for the hematologic manifestations of acute exacerbations of SLE while reducing the anti-DNA Ab level. DNA will be bound to activated charcoal which has been primed with trichlorovinylsilane using gamma radiation, and quantified using standard methods. The capacity of DNA-charcoal to bind monoclonal anti-DNA Ab from purified protein solution or serum will be determined using an ELISA method. The rheologic properties of the DNA- charcoal suspension affecting its behavior in the PF sorbent pumping system will also be evaluated. PROPOSED COMMERCIAL APPLICATION: Systemic lupus erythematosus (SLE) is a chronic, relapsing immune disorder, the severity of which is linked to anti-DNA antibody levels. The Lupus Foundation estimates that approximately 1.4 million Americans have SLE, and that 75% of patients will experience severe episodes which may be treatable with DNA immunoadsorption. DNA immunoadsorption has the potential to reduce morbidity and organ damage in these patients by reducing or eliminating the anti-DNA antibodies and possibly obviating the need for drug therapies with severe toxic side effects.

描述：（改编自申请人的摘要）长期 该建议的目的是开发基于体外的吸附剂 全身性红斑狼疮（SLE）和其他免疫学的治疗 疾病。 SLE的定义特征是在血液中的存在 抗DNA抗体（AB），其水平与 疾病症状的严重程度。 当前的治疗略有效率 或受严重副作用的限制。 基于生物-DT吸附剂 血液透析系统已被证明可用于治疗肝衰竭 昏迷。 通过将其与PF结合来增强该技术 辅助系统允许直接处理血浆 粉状吸附剂去除大或蛋白质结合的分子。 使用DNA 生物DTPF的PF单位中的免疫吸附剂将提供一种治疗 对于SLE急性加重的血液学表现 降低抗DNA AB水平。 DNA将与活化的木炭绑定 使用伽马辐射将其用三氯丙基硅烷素启动，并且 使用标准方法量化。 DNA-Choal结合的能力 来自纯化蛋白质溶液或血清的单克隆抗DNA AB将是 使用ELISA方法确定。 DNA-的流变特性 木炭暂停影响其在PF吸附剂抽水中的行为 系统也将进行评估。 拟议的商业应用： 全身性红斑狼疮（SLE）是一种慢性复发的免疫 疾病，其严重程度与抗DNA抗体水平有关。 狼疮基金会估计约有140万美国人 有SLE，有75％的患者会经历严重的发作 可以用DNA免疫吸附治疗。 DNA免疫吸收具有 通过通过 减少或消除抗DNA抗体，并可能避免 需要具有严重有毒副作用的药物疗法。